Aarti Drugs Ltd FY26: The Amine Turnaround meets the Chinese Barrier

Section 1 — At a Glance

Aarti Drugs Ltd concluded FY26 with a net revenue from operations of ₹2,565.31 crore, marking a 7.47% recovery after consecutive periods of top-line contraction. However, the company’s operating efficiencies remained under considerable stress, with full-year EBITDA coming in at ₹311.60 crore and net profits settling at ₹194.92 crore. While an initial glance suggests structural resilience—bolstered by a 15.91% expansion in net profit —the internal mechanism of this recovery shows deep friction. Investor attention is increasingly drawn to the scale-up of the newly commissioned greenfield facilities at Sayakha and Tarapur, which represent a capital deployment cycle exceeding ₹600 crore. Yet, what is fueling market anxiety is a parallel combination of high-cost inventory unloads, localized input shortages, and an aggressive, low-cost pricing barrier mounted by Chinese competitors. Operating leverage remains a theoretical promise until capacity utilizations clear historical thresholds. Profitability cannot be sustained by volumetric growth alone if realization pricing is dictated by external trade dumping. The core dilemma for the upcoming fiscal year lies in whether structural backward integration can outpace global margin deflation, a question that remains unanswered as the company enters its next commercial phase.

Section 2 — Introduction

Aarti Drugs occupies a heavily commoditized yet essential tier within the domestic pharmaceutical infrastructure, operating as a primary bulk drug synthesiser. Established in 1984 under the broader umbrella of the Aarti Group, the company has grown from a domestic manufacturer into an export-heavy supplier spanning over 100 countries.

The rationale for evaluating the company at this precise junction stems from its emergence from a heavy capital expenditure cycle. Over the last few years, the management chose to address severe industry price erosion by double-downing on domestic asset ownership—funding greenfield expansions primarily through internal accruals. This strategy has led to the recent commercialization of the Sayakha plant in late 2025. However, this operational expansion coincides with a period of severe supply chain vulnerability and legal disputes, including an ongoing indirect tax confrontation regarding a ₹230.70 crore IGST demand that has reached the Supreme Court. This piece untangles the structural realities behind the headline numbers.

Section 3 — Business Model: WTF Do They Even Do?

Aarti Drugs functions essentially as a high-volume chemical kitchen for the global pharmaceutical sector. It produces Active Pharmaceutical Ingredients (APIs), pharma intermediates, and specialty chemicals. If you have ever taken a generic antibiotic, an anti-diabetic pill like Metformin, or an anti-inflammatory drug, there is a high probability you have consumed their chemistry.

[Active Pharmaceutical Ingredients (76.5% Revenue)] ──► Large scale synthesis (Metformin, Fluoroquinolones)
[Formulations via Pinnacle (12.8% Revenue)] ──► Value-added Tablets & Capsules (OSD, Oncology)
[Specialty Chemicals & Intermediates (10.7% Revenue)] ──► Backward integration feed & Benzene chemistries

The revenue architecture relies heavily on APIs, which constitute 76.5% of the total revenue mix. Formulations—handled by its wholly-owned subsidiary, Pinnacle Life Science—account for 12.8%, while specialty chemicals and intermediates make up the remaining 10.7%. While they maintain dominant global volume shares in legacy molecules like Fluoroquinolones and Ketoconazole, the business model is inherently sensitive to raw material fluctuations and price-cutting from overseas competitors, making structural self-sufficiency the ultimate goal.

Section 4 — Financials Overview

Figures are consolidated, in ₹ crore.

Quarterly and Full-Year Performance Trend

The quarterly trend indicates a sharp drop in performance during Q3 FY26, where EBITDA margins slipped to a dismal 9.3% due to a voluntary shutdown for European audit preparation and localized ammonia shortages. Volumetric growth without structural margin support is simply running faster to stay in the same place.

What is Management Promising in the Coming Quarters?

During the recent investor calls, management pointed to a definitive structural pivot. The newly commissioned Sayakha facility, which produces methylamines used as building blocks for Metformin, was operating at a low 30% utilization in late FY26. The COO noted that captive requirements are currently met only at a 10% to 15% rate, but are projected